At least two investment firms upgraded Prestige Brands' (NYSE:PBH) stock July 9 on news it had acquired a small Australian firm giving it access to the Asia/Pacific region. While there's a lot to like about the branded over-the-counter drug company, its stock's trading at 27 times earnings. Is there enough growth to justify this type of multiple? Should you be buying? I'll have a look. 
 
Over The Counter
This is the company's only focus. With the health and wellness trend becoming mainstream, Prestige Brands is nicely positioned to take advantage of this. Its 14 core brands, which include Chloraseptic, Gaviscon, Efferdent and Clear Eyes, represent 70% of its fiscal 2013 revenue of $624 million. When CEO Matt Mannelly was hired in September 2009, its annual revenue was $293 million. By the end of March, 2013, its revenues had more than doubled as a result of three acquisitions totaling $943 million that Mannelly undertook in fiscal 2011 and 2012. Adding 23 different brands including 17 it picked up from GlaxoSmithKline (NYSE:GSK) for $663 million; it's made itself more attractive both as a possible acquisition for a larger consumer products company but also to any smaller companies looking to partner with a larger, more stable business. Whichever way the wind blows, Mannelly's put Prestige shareholders in a position to benefit. 

SEE: Strategies For Quarterly Earnings Season
 
Adding products if it doesn't lead to greater profits simply doesn't make any sense. In fiscal 2013, Prestige Brands achieved several records including revenues of $624 million, a gross margin of 56.6%, an EBITDA margin of 34.9%, $138 million in cash flow, $127 million in free cash flow and 52% adjusted earnings per share growth. Of course, none of this was achieved without paying a price. Its long-term debt at the end of March 2010 was $328 million. By the end of March this year it had risen to $978 million, almost three times the amount. As a result of the increased debt, its interest expense increased to $84.4 million with a 7.9% cost of funds, 120 basis points higher than in 2012. However, as long as the company can keep growing margins on a quarterly basis, it'll do just fine. As it stands now, its EBITDA margin of 35% is 380 basis points higher than the industry median of 21.2% and better than both Johnson & Johnson (NYSE:JNJ) and Colgate-Palmolive (NYSE:CL). Furthermore, it paid approximately 7.2 times EBITDA for the three acquisitions and now it's valued at 12 times EBITDA, suggesting the 23 brands have added $500 million in value to the company. 

EPS Growth
The company has a simple formula: If it can continue to grow its core over-the-counter business by 1-2% above than the industry average, generate more than $125 million in free cash flow per year leading to faster debt reduction, and continue to generate attractive M&A transactions, its stock will continue to deliver tremendous upside. To the end, the last 12 quarters it's outperformed the industry average by more than 1-2%; Its free cash flow over the last four years has grown by 18% annually on a compound basis; and just yesterday it made a small deal to buy Care Pharmaceuticals in Australia, which gives its OTC products immediate access to the Asian market. Given its ability to generate free cash combined with a strong operational focus, Prestige Brands could borrow as much as $2.4 billion in the next couple of years and still have a healthy balance sheet. While it's doubtful it will be able to find such a beast; it's nice to know it could.

Bottom Line
B. Riley analyst Linda Bolton Weiser believes that Prestige Brands will find another target within the next 6-12 months. If it does it generates additional cash flow. If not, it pays down its another $125 million in debt. Ultimately she believes it will be acquired for $48 per share or 17 times free cash flow. Either way, shareholders win. 
 
Most of what it sells isn't sexy. They're definitely not Michael Kors (NYSE:KORS). But we all need its products from time to time and because they aren't very expensive, we tend to lose them occasionally and have to buy more. In other words, it's very much a consumables business with little capital spending required to keep the products rolling off the lines. Can you think of a better business model? I can't.
 
Should you buy its stock at 27 times earnings? I say go for it. But then again, I wouldn't be selling in two or three months. Good things sometimes take time.  

Related Articles
  1. Investing

    How to Ballast a Portfolio with Bonds

    If January and early February performance is any guide, there’s a new normal in financial markets today: Heightened volatility.
  2. Stock Analysis

    Performance Review: Emerging Markets Equities in 2015

    Find out why emerging markets struggled in 2015 and why a half-decade long trend of poor returns is proving optimistic growth investors wrong.
  3. Investing News

    Today's Sell-off: Are We in a Margin Liquidation?

    If we're in market liquidation, is it good news or bad news? That party depends on your timeframe.
  4. Investing News

    Bank Stocks: Time to Buy or Avoid? (WFC, JPM, C)

    Bank stocks have been pounded. Is this the right time to buy or should they be avoided?
  5. Stock Analysis

    Why the Bullish Are Turning Bearish

    Banks are reducing their targets for the S&P 500 for 2016. Here's why.
  6. Stock Analysis

    How to Find Quality Stocks Amid the Wreckage

    Finding companies with good earnings and hitting on all cylinders in this environment, although possible, is not easy.
  7. Investing News

    What You Can Learn from Carl Icahn's Mistakes

    Carl Icahn has been a stellar performer in the investment world for decades, but following his lead these days could be dangerous.
  8. Stock Analysis

    Analyzing Altria's Return on Equity (ROE) (MO)

    Learn about Altria Group's return on equity (ROE) and analyze net profit margin, asset turnover and financial leverage to determine what is causing its high ROE.
  9. Investing News

    Icahn's Bet on Cheniere Energy: Should You Follow?

    Investing legend Carl Icahn continues to lose money on Cheniere Energy, but he's increasing his stake. Should you follow his lead?
  10. Stock Analysis

    Analyzing Google's Return on Equity (ROE) (GOOGL)

    Learn about Alphabet's return on equity. How has its ROE changed over time, how does it compare to its peers and what factors are driving ROE for the company?
RELATED FAQS
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>
COMPANIES IN THIS ARTICLE
Trading Center